source
- FDA approves Lilly's new combination therapy for advanced breast cancerThe U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…
- Novo presents low-dose CagriSema data showing competitiveness ahead of approval decisionNovo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…